Heron Therapeutics (HRTX) Tops Q4 EPS by 15c

Heron Therapeutics (NASDAQ: HRTX) reported Q4 EPS of ($0.17), $0.15 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $30.03 million versus the consensus estimate of $27.24 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Hub Group faces credibility test as Q2 report looms Sept. 1
• Benchmark Reiterates Buy Rating on Marvell (MRVL) Following Earnings